Skip to search formSkip to main contentSkip to account menu

L-826,141

Known as: 4-(2-(3,4-bis-difluoromethoxyphenyl)-2-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-ethyl)-3-methylpyridine-1-oxide 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Pyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Lack of clinical efficacy of a phosphodiesterase-4 inhibitor for treatment of heaves in horses.
Phosphodiesterase-4 (PDE 4) enzyme inhibitors have been shown to have anti-inflammatory properties in various animal disease… 
2002
2002
Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters.
2002
2002
Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)